Navigation Links
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
Date:1/9/2009

e and recent data show the OA market to be growing by three percent annually. At this rate the U.S. patient population will grow to 60 million by 2020.

About ESBATech's antibody fragment platform technology

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks. ESBATech's unique, scientific approach to stabilize monomeric, single-chain antibody fragments (scFvs) using its proprietary fully-human antibody fragment frameworks has elucidated the drug-like properties of these proprietary scFvs. The company is advancing a pipeline of novel antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The Company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. The Company focuses on three franchises: ophthalmology, rheumatology and respiratory. In ophthalmology, the Company has successfully completed clinical Phase I development of ESBA105 administered topically via eye drops for inflammatory eye diseases.

Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBAT
'/>"/>

SOURCE ESBATech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
6. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
7. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
8. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 /PRNewswire/ ... and manufacturing, announced that Mr. Greg Weilersbacher joined ... Control on August 25, 2014. Greg ... pharmaceutical industry experience with focused expertise in Quality ... Mr. Weilersbacher brings to Formex ...
(Date:9/16/2014)... Sept. 16, 2014 On September 25 to ... focusing on medical design and manufacturing - MEDTEC China ... World Expo Exhibition & Convention Center, bringing together close ... regions to showcase their latest medical-grade raw materials, parts ... one week remaining for free visitor pre-registration to be ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... April 11, 2012  On April 16, the U.S. Supreme Court ... Labor Standards Act, Christopher v. SmithKline Beecham Corp. ... representatives are eligible to receive overtime pay. The larger issue ... of Labor,s interpretation of that statute. The ...
... N.C., April 10, 2012  TSI Healthcare announced today ... attested to successfully meeting "Meaningful Use" requirements of ... Systems. These providers completed data collection last year ... period for the Federal Government sponsored EHR Incentives ...
Cached Medicine Technology:Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler 2Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler 3TSI Healthcare Customers Receive Government Incentives for Meeting EHR Requirements 2
(Date:9/16/2014)... An experienced review website, Top10BestSEOHosting.com, has recently ... Bluehost and HostGator.com are among the best hosting ... high quality web hosting (including VPS and cloud ... now. , BlueHost ( http://www.bluehost.com/track/seohosts ) has ... a reliable and long-standing force in the world ...
(Date:9/16/2014)... The second federal bellwether trial involving ... subsidiary Ethicon concluded with the jury in the case ... her $3.27 million in damages, according to a September ... found Ethicon liable for selling faulty devices and failing ... at risk from side effects that include pain, bleeding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... September 16, 2014 Not all recovery ... take care to make sure all their patients are ... some, this may include the newly-introduced online therapy. Millennium ... which gives patients the opportunity to seek treatment from ... provide medical and clinical care at a distance. They ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3
... a snack between breakfast and lunch lose less weight compared ... a study led by researchers at Fred Hutchinson Cancer Research ... McTiernan, M.D., Ph.D., a member of the Hutchinson Center,s Public ... be published in the December issue of the Journal ...
... moment to go with a method Princeton University researchers ... the chances of an unexpected yet groundbreaking chemical discovery. ... Science a technique to accomplish "accelerated serendipity" ... reactions a day with molecules never before combined. In ...
... release is available in French . , ... consequences than previously believed. Recent data suggests that individuals who ... to have a heart attack compared to individuals who are ... until now. A new study led by Concordia University ...
... of recent experiences. Scientists from Ludwig-Maximilians-Universitt (LMU) in ... subjects to estimate distances in a virtual reality ... approach the mean of all previously experienced distances. ... accurately predict the experimental findings using a mathematical ...
... London, November 28, 2011 - Serious global discussions have begun ... of 2015. Governments and international agencies are asking what has ... best to proceed after the deadline. Against this backdrop, a ... Health Matters finds that "quick impact" strategies, which may ...
... NJ. November 23, 2011. Kessler Foundation received two ... race/ethnicity, and socioeconomic status on the rehabilitation and ... grants totalling $296,261 were awarded to Denise Fyffe, ... Injury/Outcomes & Assessment Laboratories. Dr. Fyffe, a clinical ...
Cached Medicine News:Health News:Mid-morning snacking may sabotage weight-loss efforts 2Health News:Mid-morning snacking may sabotage weight-loss efforts 3Health News:Princeton technique puts chemistry breakthroughs on the fast track 2Health News:Princeton technique puts chemistry breakthroughs on the fast track 3Health News:Princeton technique puts chemistry breakthroughs on the fast track 4Health News:Princeton technique puts chemistry breakthroughs on the fast track 5Health News:Depression can lead to heart disease 2Health News:When errors improve performance: Model describes how experiences influence our perception 2Health News:Good intentions may hamper progress in pursuit of global reproductive health and rights 2Health News:Kessler Foundation receives grants to study health disparities in people with disabilities 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducers with guidewires....
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: